StreetAlpha.app
Home › Stocks › KYNB

Kyntra Bio, Inc. (KYNB)

$1.56
▼ −14.75%
LAST CLOSE · NOV 20

Kyntra Bio develops cancer and anemia treatments, including a prostate cancer drug candidate and roxadustat, from San Francisco. It last closed at $1.56 on Nov 20, down 14.75% on the day. The next earnings report for KYNB is expected around Mon, Mar 15, 2027, after the close. For the quarter ended Sep 2026, KYNB reported EPS of $0.04 on revenue of $1.8M, with revenue up 63.8% from a year ago. Over its last 6 reports the stock moved an average of 11.3% the session after earnings.

AI Auto Pilots
Is KYNB in one of our AI portfolios?
Five AI traders run real portfolios in the open, with every decision logged. Create a free account to see if they hold KYNB.

Key Stats

Last 12 months
Results
Revenue
$5.3M
−36.1% vs a year ago
Net income
−$17.3M
−108.0% vs a year ago
EPS (diluted)
−$4.29
−108.0% vs a year ago
Free cash flow
−$48.5M
−913.7% margin
Valuation
Market cap
$6.3M
4.0M shares
P/E
–
No P/E while losing money
Price to sales
1.2
Market cap over revenue
Dividend yield
None
No dividend in 12 months
Balance sheet
Cash & equivalents
$9.9M
At Sep 30
Shareholder equity
−$29.2M
Shares outstanding
4.0M
At Oct 13
Fiscal year endsDecember
ExchangeNasdaq
Financials history
FY2021: $235.3M$235.3MFY2021FY2022: $140.7M$140.7MFY2022FY2023: $46.8M$46.8MFY2023FY2024: $29.6M$29.6MFY2024FY2025: $6.4M$6.4MFY2025

From KYNB's SEC filings, latest 10-Q for the period ending Sep 30, 2026 (filed Nov 16). Last 12 months adds up the four latest quarters.

Next report
Mar 15
Estimated date · After the close
Reported EPS
$0.04
Quarter ended Sep 2026
Year ago EPS
$49.61
−99.9% on a GAAP basis
Revenue
$1.8M
+63.8% vs a year ago
Estimates and implied move
Consensus forecasts and the move options price in
EPS by quarter (GAAP)
Dec 2024: $4.54Dec '24Mar 2025: $1.15Mar '25Jun 2025: -$1.88Jun '25Sep 2025: $49.61Sep '25Dec 2025: -$3.53Dec '25Mar 2026: -$3.76Mar '26Jun 2026: $2.96Jun '26Sep 2026: $0.04Sep '26Latest $0.04
Revenue by quarter
Dec 2024: $3.1MDec '24Mar 2025: $2.7MMar '25Jun 2025: $1.3MJun '25Sep 2025: $1.1MSep '25Dec 2025: $1.3MDec '25Mar 2026: $3.7MMar '26Sep 2026: $1.8MSep '26Latest $1.8M
How KYNB moved after its last 6 reports
Average move the session after a report ±11.3%
Nov 16, 2026After the close−36.3%
Aug 13, 2026After the close+0.1%
May 11, 2026After the close+6.3%
Mar 16, 2026After the close+5.3%
Nov 10, 2025After the close−9.6%
Aug 11, 2025After the close+10.5%
Close to close, the session after each report, adjusted for splits. Past moves are no guide to the next one.
StreetAlpha's call on KYNBStart your 7 day free trial to see StreetAlpha's call before the report, with the options flow, dark pool, history and technical scores behind it.Sign up freeSign in

Analyst Ratings & Price Targets

Analyst Ratings →
AI Starter and AI Pro
Full analyst coverage on KYNB
  • Every upgrade, downgrade and initiation as it happens
  • Every price target change, raised or cut
  • Consensus rating with the average, high and low targets
  • Each firm's full rating history on KYNB

Technical Analysis

KYNB · as of the Nov 20 close · updated each morning
Downtrend, oversold

The stock is 130% below its 20 day and 236% below its 50 day average. It is 330% below its 200 day average, so the longer trend is down. Momentum is weak (RSI 12), oversold. The nearest support is the Pivot S1 at $1.46, and the nearest resistance the Pivot at $1.66.

Short trendBearish
Long trendBearish
MomentumWeak
StretchOversold
VolatilityHigh, 28.1%/day
Key levels
$10.4752 week high+571.2%
$6.71200 day average+330.1%
$6.33100 day average+305.8%
$5.2450 day average+235.9%
$4.85Swing high (Oct 29)+210.9%
$3.5920 day average+130.1%
$1.75Pivot R1+12.2%
$1.66Pivot+6.4%
$1.5652 week low+0.0%
$1.56Last close
$1.46Pivot S1−6.4%
Indicators
RSI (14)12.17Oversold below 30Oversold
MACD-0.94Below its signal lineBearish
Stochastic1.9Near the bottom of its rangeOversold
ADX (14)51.8Strong downtrend
Williams %R-99.9Oversold below −80, overbought above −20Oversold
CCI (20)-180.2Oversold below −100, overbought above 100Oversold
Rate of change−58.2%Change over 10 sessionsBearish
ATR (14)$0.44Typical daily range, 28.1% of price
MA 10Below
MA 20Below
MA 50Below
MA 100Below
MA 200Below
What happened before, for KYNB

What happened before

See how KYNB did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record. Free with an account.

November seasonalityHow KYNB usually does this month. See Seasonality

Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.

AI Day Trader
Watch Claude day trade the open, live.
Every session it trades SPY, QQQ, IWM and two daily stock picks, with each call logged before the move.

Seasonality

How KYNB has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2014.

Loading…

See the stocks that usually rise in November →

Whale Options Flow

90D
Whale options flow for KYNBHow many large options trades hit KYNB, the bullish and bearish split, and every trade with strike, premium and expiry are shown to AI Starter and AI Pro members.Sign up freeSign in

See today’s whale options flow across the market →

KYNB Institutional Ownership

Full report →
Fund sentiment · Q3 2026
Strongly bullish
Strongly bearishNeutralStrongly bullish
  • ▲11 buying vs 6 selling
  • ▲Held by funds +1.6 pts
  • ▲Funds holding +7
  • ▲Superinvestors: 2 added, 0 cut
  • ●Put/call not meaningful
Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Funds holdingHeld by funds %
Q3 2026This quarterLast quarterChange
Funds holding3528+25.0%
In funds' top 1000–
Held by funds26.2%24.7%+1.6 pts
New / increased7 / 41 / 4+120.0%
Reduced / sold out6 / 07 / 5−50.0%
Put/call ratio–––
Top holders, biggest buyers and sellers, 8 quarters of charts and this season's filings so far.See KYNB institutional ownership →

From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.

KYNB Insider Trading

All filings →
Insider trading · 12 months
No open market trades in 12 months
Bought$00 buys · 0 insiders
Sold$00 sales · 0 insiders
DecMarJunSep
BoughtSoldlast 12 months
Trade dateInsiderTypeSharesPriceValue
Nov 17, 2025Thane WettigCEOBuy3,700$9.12$34K
Jun 30, 2025James A SchoeneckDirectorBuy23,567$5.07$119K
Mar 24, 2025Thane WettigCEOBuy145,000$0.35$51K
Mar 21, 2025James A SchoeneckDirectorBuy300,000$0.35$105K
Every insider buy and sale for KYNB over 2 years, with a link to each SEC filing. AI Pro members can get an alert the moment an insider trades.See KYNB insider trades →

From SEC Form 4 filings by KYNB's officers, directors and 10% owners. Open market buys and sales only; option exercises, gifts, awards and tax withholding are left out. Not investment advice.

AI Auto Pilots

Paper trading

StreetAlpha runs autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether KYNB is in one of them and how their past KYNB trades turned out.

KYNB in the AI portfolios
Loading…

KYNB News Tone and Price

Loading…

Macro & Market News

All StreetAlpha news →

StreetAlpha hasn't covered KYNB in an article yet. Here's the latest on the wider market.

KYNB in the news

About Kyntra Bio

Kyntra Bio is a biopharmaceutical company in San Francisco, California, that develops treatments for cancer and anemia. Its lead program, FG-3246, is a drug candidate for advanced prostate cancer, paired with FG-3180, an imaging agent that helps identify suitable patients. The company also holds rights to roxadustat, a treatment for anemia in patients with chronic kidney disease, and is developing it for a blood disorder called myelodysplastic syndromes.

Headquarters
San Francisco, CA